Exploring lipid biomarkers of coronary heart disease for elucidating the biological effects of gelanxinning capsule by lipidomics method based on liquid chromatography mass spectrometry

High-throughputl ipidomics technology was used to explore the potential therapeutic targets and mechanism of gelanxinning capsule on rat model with coronary heart disease, which attempt to provide a novel method to interpret the molecule mechanism of traditional medicine. The lipid markers of coronary heart disease were determined in full-scan analysis based on ultra-performance liquid chromatography-high-definition mass spectrometry. Then, the metabolic changes associated with gelanxinning capsule treatment via the modulation of lipid biomarkers and pathway in rats was characterized. After gelanxinning treatment, the metabolic profile tends to recover compared with the model group. A total of twenty-six potential biomarkers was identified to represent the disorders of lipid metabolism in coronary heart disease animal model, which nineteen of them were regulated by gelanxinning capsule administration, and fourmetabolic pathways includingglycerophospholipid metabolism, sphingolipid metabolism, glycosylphosphatidylinositol-anchor biosynthesis and glycerolipid metabolism were involved. From the pathway analysis, it was found that glycerophospholipid metabolism and sphingolipid metabolism with significant differences have potential to be regarded as new targets for the treatment of coronary heart disease. Gelanxinning capsule protects against coronary heart diseasewith good therapeutic effect by regulating lipid biomarkers and pathway from lipidomics-guided biochemical analysis.